Renephra and Myconostica are part of the UMIP Premier Fund which is managed by technology specialists MTI Partners, who invest in hi-tech, high growth companies.
Myconostica was awarded the ‘Innovation in Diagnostics Project of the Year’, at this year’s Northwest Biomedical Awards dinner, whilst Renephra received the ‘Emerging Technology Project of the Year’ at the same ceremony, but also scooped a ‘Northwest NHS Innovations Award’ at a separate event.
University of Manchester School of Medicine spin out, Myconostica, is a medical diagnostic company which develops and commercialises rapid and highly specific tests for life-threatening fungal infections. The award was received for Myconostica’s MycArray Yeast ID product; an inventive system for identifying Candida species.
Renephra, also a spin out project from The University of Manchester, were recognised for the development of their groundbreaking dialysis technology that could dramatically improve the quality of life of patients with kidney disease and improve their long term prognosis.
Dr. John Thornback, Myconostica’s Chief Operating Officer, received the honour on behalf of the company at the award ceremony. Speaking at the event, Dr. Thornback said “Myconostica is delighted to have received this title in recognition of the innovative technology utilised in our original test for identifying Candida species, MycArray Yeast ID.
Dr. Thornback continues: “Having been the recipients of Bionow’s Biomedical Start Up of the Year Award in 2006 we are delighted to have been further recognised for our continued contribution to providing innovative diagnostic solutions for the treatment of invasive fungal diseases.”
Prof. Paul Brenchley said: “Receiving one award is fantastic, so to have our technology recognised by both the Northwest NHS Innovations Award and the Northwest Biomedical Awards in one week is a huge honour.”
Manchester based MTI Partners Investment Manager Mark Rahn said: “I am delighted that the University of Manchester and NHS projects have featured so well in recent awards events. MTI’s UMIP Premier Fund is a supporter of both Myconostica and Renephra and we are pleased that these awards recognise their recent strides forward.”
Over 200 people from the Northwest’s biomedical sector gathered last night (Thursday 12th November) at the annual Northwest Biomedical Awards at Mere Golf and Country Club.
The awards, organised by Bionow, the Northwest Regional Development Agency’s (NWDA) biomedical cluster support group, were a resounding success and showcased the very best of the region’s world class biotechnology sector.
Mark Hughes, NWDA Executive Director of Economic Development, said:
“England’s Northwest is one of the UK’s top three biomedical clusters, home to world class biotechnology companies and internationally renowned research capability in this sector. The Northwest Biotechnology Awards recognises excellence in the sector and rewards the success and achievements of the people and organisations that are making a significant contribution to the industry and the region.”
The winners were:
Biomedical Project of the Year (sponsored By Pannone LLP)
Winner: ICX-RHY Project, Intercytex
Healthcare Project of the Year (sponsored By TrusTech/NHS)
Winner: The Oesophageal Doppler guided intraoperative fluid management in major surgery, Central Manchester University Hospitals NHS Foundation Trust
Innovation in Diagnostics Project of the Year (sponsored by ThermoFisher)
Winner: Candidaemia Species, Myconostica
Promising Biomedical Technologist of the Year (sponsored by Novartis Vaccines)
Winner: Dr Christian Zakian, University of Manchester
Emerging Technology Project of the Year (sponsored by Waters Corporation)
Winner: Renephra, Central Manchester University Hospitals NHS Foundation Trust
Biomedical Start Up Company of the Year (sponsored by Baker Tilly)
Winner: Biofortuna Ltd
Biomedical Company of the Year (sponsored by AstraZeneca/MedImmune)
Winner: Advanced Medical Solutions
Personality of the Year – Dr Sharon O’Kane, Renovo
Outstanding Contribution – Dr Linda Magee, MAHSC
Dr Christian Zakian from the School of Dentistry at The University of Manchester has been awarded a prestigious accolade for his pioneering work in the biomedical field.
Christian claimed the ‘Promising Northwest Biomedical Technologist of the Year’ at the North West Biomedical Awards for his work on an invention that allows mapping of carious lesions in the teeth. The Awards, which are organised by BioNow, examine the best emerging talent in the region and reward excellence in the sector.
The novel approach of using defined wavelengths of light to build an image of each tooth allowing dentists to not only determine that decay is present but how deep that decay extends. To date, available techniques are either not sensitive enough to early stages of the disease, such as x-rays, or are limited by the presence of stain in teeth. This method is non-invasive and can assist dentists to monitor the disease progression, resulting in a more informed approach to treatment. In contrast to other optical techniques this innovation provides a picture of the whole tooth and not just a single point; this is useful to reveal the precise location of the decay and helping to decide whether drilling is required and where. The images produced are clear and bright and offer an opportunity for patient involvement in the treatment decision making processes.
Led by Christian, his research team applied for Proof-of-Principle funding from UMIP to bring the project forward, which was subsequently granted. Christian is part of a multi-disciplinary research group (Dental Health Unit) led by Prof. Roger Ellwood and Dr. Iain Pretty and formed by scientists and dentists who focused on coordinating clinical trials and developing next generation dental diagnostic instruments.
UMIP licensing manager, Dr Lizzie Crawford, commented on the awards: “The investment from UMIP allowed Christian to go from strength to strength, transcending his daily role as a research assistant to head up a team that includes, a technician and a research assistant. Christian’s ability to commercialise and drive his product forward at such an early stage in his career is testament to his tenacity and confidence in his invention and this was a view that was clearly shared by the judging panel.”